nodes	percent_of_prediction	percent_of_DWPC	metapath
Moclobemide—MAOB—Alpha-synuclein signaling—KLK6—ovarian cancer	0.0112	0.161	CbGpPWpGaD
Moclobemide—MAOB—myometrium—ovarian cancer	0.00575	0.066	CbGeAlD
Moclobemide—MAOB—embryo—ovarian cancer	0.00553	0.0634	CbGeAlD
Moclobemide—MAOA—myometrium—ovarian cancer	0.0049	0.0563	CbGeAlD
Moclobemide—MAOA—embryo—ovarian cancer	0.00472	0.0541	CbGeAlD
Moclobemide—MAOB—uterine cervix—ovarian cancer	0.00447	0.0513	CbGeAlD
Moclobemide—MAOB—decidua—ovarian cancer	0.00426	0.0489	CbGeAlD
Moclobemide—MAOB—endometrium—ovarian cancer	0.00405	0.0464	CbGeAlD
Moclobemide—MAOB—Dopamine metabolism—SOD1—ovarian cancer	0.00389	0.0557	CbGpPWpGaD
Moclobemide—MAOA—uterine cervix—ovarian cancer	0.00382	0.0438	CbGeAlD
Moclobemide—MAOB—uterus—ovarian cancer	0.00373	0.0428	CbGeAlD
Moclobemide—MAOA—decidua—ovarian cancer	0.00364	0.0417	CbGeAlD
Moclobemide—MAOA—endometrium—ovarian cancer	0.00345	0.0396	CbGeAlD
Moclobemide—MAOB—female reproductive system—ovarian cancer	0.00335	0.0385	CbGeAlD
Moclobemide—MAOA—uterus—ovarian cancer	0.00318	0.0365	CbGeAlD
Moclobemide—MAOB—Alpha-synuclein signaling—PARK2—ovarian cancer	0.00311	0.0447	CbGpPWpGaD
Moclobemide—MAOB—female gonad—ovarian cancer	0.00305	0.035	CbGeAlD
Moclobemide—MAOB—vagina—ovarian cancer	0.00303	0.0348	CbGeAlD
Moclobemide—MAOA—female reproductive system—ovarian cancer	0.00286	0.0328	CbGeAlD
Moclobemide—MAOB—testis—ovarian cancer	0.0027	0.031	CbGeAlD
Moclobemide—Hypotension—Vinorelbine—ovarian cancer	0.00267	0.00317	CcSEcCtD
Moclobemide—Pruritus—Chlorambucil—ovarian cancer	0.00266	0.00315	CcSEcCtD
Moclobemide—Urticaria—Topotecan—ovarian cancer	0.00266	0.00315	CcSEcCtD
Moclobemide—Abdominal pain—Topotecan—ovarian cancer	0.00265	0.00314	CcSEcCtD
Moclobemide—CYP2C19—vagina—ovarian cancer	0.00264	0.0303	CbGeAlD
Moclobemide—Visual impairment—Paclitaxel—ovarian cancer	0.00261	0.0031	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00261	0.00309	CcSEcCtD
Moclobemide—Urticaria—Melphalan—ovarian cancer	0.0026	0.00309	CcSEcCtD
Moclobemide—MAOA—female gonad—ovarian cancer	0.0026	0.0299	CbGeAlD
Moclobemide—MAOA—vagina—ovarian cancer	0.00259	0.0297	CbGeAlD
Moclobemide—Diarrhoea—Chlorambucil—ovarian cancer	0.00257	0.00305	CcSEcCtD
Moclobemide—Paraesthesia—Vinorelbine—ovarian cancer	0.00257	0.00305	CcSEcCtD
Moclobemide—Dyspnoea—Vinorelbine—ovarian cancer	0.00255	0.00303	CcSEcCtD
Moclobemide—Tinnitus—Paclitaxel—ovarian cancer	0.00253	0.003	CcSEcCtD
Moclobemide—Flushing—Paclitaxel—ovarian cancer	0.00252	0.00298	CcSEcCtD
Moclobemide—Stomatitis—Docetaxel—ovarian cancer	0.00249	0.00296	CcSEcCtD
Moclobemide—Decreased appetite—Vinorelbine—ovarian cancer	0.00249	0.00295	CcSEcCtD
Moclobemide—Conjunctivitis—Docetaxel—ovarian cancer	0.00249	0.00295	CcSEcCtD
Moclobemide—Fatigue—Vinorelbine—ovarian cancer	0.00247	0.00293	CcSEcCtD
Moclobemide—Constipation—Vinorelbine—ovarian cancer	0.00245	0.0029	CcSEcCtD
Moclobemide—MAOA—Dopamine metabolism—SOD1—ovarian cancer	0.00244	0.035	CbGpPWpGaD
Moclobemide—Asthenia—Topotecan—ovarian cancer	0.0024	0.00285	CcSEcCtD
Moclobemide—Hot flush—Epirubicin—ovarian cancer	0.00239	0.00284	CcSEcCtD
Moclobemide—Vomiting—Chlorambucil—ovarian cancer	0.00239	0.00283	CcSEcCtD
Moclobemide—Menopausal symptoms—Epirubicin—ovarian cancer	0.00237	0.00282	CcSEcCtD
Moclobemide—Pruritus—Topotecan—ovarian cancer	0.00237	0.00281	CcSEcCtD
Moclobemide—Feeling abnormal—Vinorelbine—ovarian cancer	0.00236	0.0028	CcSEcCtD
Moclobemide—Asthenia—Melphalan—ovarian cancer	0.00235	0.00279	CcSEcCtD
Moclobemide—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00234	0.00278	CcSEcCtD
Moclobemide—Flatulence—Paclitaxel—ovarian cancer	0.00232	0.00276	CcSEcCtD
Moclobemide—Pruritus—Melphalan—ovarian cancer	0.00232	0.00275	CcSEcCtD
Moclobemide—Tension—Paclitaxel—ovarian cancer	0.00231	0.00275	CcSEcCtD
Moclobemide—Dysgeusia—Paclitaxel—ovarian cancer	0.00231	0.00274	CcSEcCtD
Moclobemide—MAOA—testis—ovarian cancer	0.00231	0.0265	CbGeAlD
Moclobemide—Nervousness—Paclitaxel—ovarian cancer	0.00229	0.00272	CcSEcCtD
Moclobemide—Diarrhoea—Topotecan—ovarian cancer	0.00229	0.00272	CcSEcCtD
Moclobemide—Urticaria—Vinorelbine—ovarian cancer	0.00227	0.0027	CcSEcCtD
Moclobemide—CYP2C9—female reproductive system—ovarian cancer	0.00226	0.026	CbGeAlD
Moclobemide—Abdominal pain—Vinorelbine—ovarian cancer	0.00226	0.00268	CcSEcCtD
Moclobemide—Diarrhoea—Melphalan—ovarian cancer	0.00224	0.00266	CcSEcCtD
Moclobemide—Osteoarthritis—Epirubicin—ovarian cancer	0.00224	0.00266	CcSEcCtD
Moclobemide—Nausea—Chlorambucil—ovarian cancer	0.00223	0.00265	CcSEcCtD
Moclobemide—Vision blurred—Paclitaxel—ovarian cancer	0.00222	0.00264	CcSEcCtD
Moclobemide—Hot flush—Doxorubicin—ovarian cancer	0.00222	0.00263	CcSEcCtD
Moclobemide—Visual impairment—Docetaxel—ovarian cancer	0.00221	0.00263	CcSEcCtD
Moclobemide—Dizziness—Topotecan—ovarian cancer	0.00221	0.00262	CcSEcCtD
Moclobemide—Tremor—Paclitaxel—ovarian cancer	0.00221	0.00262	CcSEcCtD
Moclobemide—Migraine—Epirubicin—ovarian cancer	0.0022	0.00261	CcSEcCtD
Moclobemide—Menopausal symptoms—Doxorubicin—ovarian cancer	0.0022	0.0026	CcSEcCtD
Moclobemide—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00219	0.0026	CcSEcCtD
Moclobemide—CYP1A2—Sulindac Metabolic Pathway—CYP1B1—ovarian cancer	0.00217	0.0311	CbGpPWpGaD
Moclobemide—Agitation—Paclitaxel—ovarian cancer	0.00217	0.00257	CcSEcCtD
Moclobemide—Flushing—Docetaxel—ovarian cancer	0.00213	0.00253	CcSEcCtD
Moclobemide—Vomiting—Topotecan—ovarian cancer	0.00213	0.00252	CcSEcCtD
Moclobemide—Malaise—Paclitaxel—ovarian cancer	0.00213	0.00252	CcSEcCtD
Moclobemide—Syncope—Paclitaxel—ovarian cancer	0.00212	0.00251	CcSEcCtD
Moclobemide—Rash—Topotecan—ovarian cancer	0.00211	0.0025	CcSEcCtD
Moclobemide—Dermatitis—Topotecan—ovarian cancer	0.00211	0.0025	CcSEcCtD
Moclobemide—Headache—Topotecan—ovarian cancer	0.0021	0.00249	CcSEcCtD
Moclobemide—Palpitations—Paclitaxel—ovarian cancer	0.00208	0.00247	CcSEcCtD
Moclobemide—Vomiting—Melphalan—ovarian cancer	0.00208	0.00247	CcSEcCtD
Moclobemide—Loss of consciousness—Paclitaxel—ovarian cancer	0.00207	0.00246	CcSEcCtD
Moclobemide—Osteoarthritis—Doxorubicin—ovarian cancer	0.00207	0.00246	CcSEcCtD
Moclobemide—Rash—Melphalan—ovarian cancer	0.00207	0.00245	CcSEcCtD
Moclobemide—Dermatitis—Melphalan—ovarian cancer	0.00206	0.00245	CcSEcCtD
Moclobemide—Asthenia—Vinorelbine—ovarian cancer	0.00205	0.00244	CcSEcCtD
Moclobemide—Dry skin—Epirubicin—ovarian cancer	0.00205	0.00243	CcSEcCtD
Moclobemide—Migraine—Doxorubicin—ovarian cancer	0.00204	0.00242	CcSEcCtD
Moclobemide—Hypertension—Paclitaxel—ovarian cancer	0.00204	0.00242	CcSEcCtD
Moclobemide—Pruritus—Vinorelbine—ovarian cancer	0.00203	0.0024	CcSEcCtD
Moclobemide—Chest pain—Paclitaxel—ovarian cancer	0.00201	0.00238	CcSEcCtD
Moclobemide—Myalgia—Paclitaxel—ovarian cancer	0.00201	0.00238	CcSEcCtD
Moclobemide—Anxiety—Paclitaxel—ovarian cancer	0.002	0.00237	CcSEcCtD
Moclobemide—Nausea—Topotecan—ovarian cancer	0.00199	0.00236	CcSEcCtD
Moclobemide—Discomfort—Paclitaxel—ovarian cancer	0.00198	0.00235	CcSEcCtD
Moclobemide—Gastritis—Epirubicin—ovarian cancer	0.00198	0.00235	CcSEcCtD
Moclobemide—Dry mouth—Paclitaxel—ovarian cancer	0.00196	0.00233	CcSEcCtD
Moclobemide—MAOB—lymph node—ovarian cancer	0.00196	0.0225	CbGeAlD
Moclobemide—Diarrhoea—Vinorelbine—ovarian cancer	0.00196	0.00232	CcSEcCtD
Moclobemide—Dysgeusia—Docetaxel—ovarian cancer	0.00196	0.00232	CcSEcCtD
Moclobemide—Abdominal distension—Epirubicin—ovarian cancer	0.00195	0.00231	CcSEcCtD
Moclobemide—Nausea—Melphalan—ovarian cancer	0.00195	0.00231	CcSEcCtD
Moclobemide—Confusional state—Paclitaxel—ovarian cancer	0.00194	0.0023	CcSEcCtD
Moclobemide—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00191	0.0274	CbGpPWpGaD
Moclobemide—Dry skin—Doxorubicin—ovarian cancer	0.0019	0.00225	CcSEcCtD
Moclobemide—Shock—Paclitaxel—ovarian cancer	0.00189	0.00225	CcSEcCtD
Moclobemide—Dizziness—Vinorelbine—ovarian cancer	0.00189	0.00225	CcSEcCtD
Moclobemide—Angina pectoris—Epirubicin—ovarian cancer	0.00189	0.00224	CcSEcCtD
Moclobemide—Tachycardia—Paclitaxel—ovarian cancer	0.00188	0.00223	CcSEcCtD
Moclobemide—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00186	0.00221	CcSEcCtD
Moclobemide—Gastritis—Doxorubicin—ovarian cancer	0.00183	0.00218	CcSEcCtD
Moclobemide—Vomiting—Vinorelbine—ovarian cancer	0.00182	0.00216	CcSEcCtD
Moclobemide—Dysuria—Epirubicin—ovarian cancer	0.00181	0.00215	CcSEcCtD
Moclobemide—Rash—Vinorelbine—ovarian cancer	0.0018	0.00214	CcSEcCtD
Moclobemide—Dermatitis—Vinorelbine—ovarian cancer	0.0018	0.00214	CcSEcCtD
Moclobemide—Abdominal distension—Doxorubicin—ovarian cancer	0.0018	0.00214	CcSEcCtD
Moclobemide—Hypotension—Paclitaxel—ovarian cancer	0.0018	0.00213	CcSEcCtD
Moclobemide—Headache—Vinorelbine—ovarian cancer	0.00179	0.00213	CcSEcCtD
Moclobemide—Syncope—Docetaxel—ovarian cancer	0.00179	0.00213	CcSEcCtD
Moclobemide—Palpitations—Docetaxel—ovarian cancer	0.00177	0.0021	CcSEcCtD
Moclobemide—Loss of consciousness—Docetaxel—ovarian cancer	0.00176	0.00208	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00175	0.00208	CcSEcCtD
Moclobemide—Angina pectoris—Doxorubicin—ovarian cancer	0.00174	0.00207	CcSEcCtD
Moclobemide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00174	0.025	CbGpPWpGaD
Moclobemide—Insomnia—Paclitaxel—ovarian cancer	0.00174	0.00207	CcSEcCtD
Moclobemide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.00174	0.0249	CbGpPWpGaD
Moclobemide—Paraesthesia—Paclitaxel—ovarian cancer	0.00173	0.00205	CcSEcCtD
Moclobemide—Hypertension—Docetaxel—ovarian cancer	0.00173	0.00205	CcSEcCtD
Moclobemide—Drowsiness—Epirubicin—ovarian cancer	0.00173	0.00205	CcSEcCtD
Moclobemide—Dyspnoea—Paclitaxel—ovarian cancer	0.00172	0.00204	CcSEcCtD
Moclobemide—Somnolence—Paclitaxel—ovarian cancer	0.00171	0.00203	CcSEcCtD
Moclobemide—Myalgia—Docetaxel—ovarian cancer	0.0017	0.00202	CcSEcCtD
Moclobemide—Chest pain—Docetaxel—ovarian cancer	0.0017	0.00202	CcSEcCtD
Moclobemide—Nausea—Vinorelbine—ovarian cancer	0.0017	0.00202	CcSEcCtD
Moclobemide—CYP2D6—female reproductive system—ovarian cancer	0.0017	0.0195	CbGeAlD
Moclobemide—Dyspepsia—Paclitaxel—ovarian cancer	0.00169	0.00201	CcSEcCtD
Moclobemide—Stomatitis—Epirubicin—ovarian cancer	0.00168	0.002	CcSEcCtD
Moclobemide—Conjunctivitis—Epirubicin—ovarian cancer	0.00168	0.00199	CcSEcCtD
Moclobemide—Dysuria—Doxorubicin—ovarian cancer	0.00167	0.00199	CcSEcCtD
Moclobemide—Decreased appetite—Paclitaxel—ovarian cancer	0.00167	0.00199	CcSEcCtD
Moclobemide—MAOA—lymph node—ovarian cancer	0.00167	0.0192	CbGeAlD
Moclobemide—Dry mouth—Docetaxel—ovarian cancer	0.00166	0.00197	CcSEcCtD
Moclobemide—Fatigue—Paclitaxel—ovarian cancer	0.00166	0.00197	CcSEcCtD
Moclobemide—Sweating—Epirubicin—ovarian cancer	0.00165	0.00196	CcSEcCtD
Moclobemide—Constipation—Paclitaxel—ovarian cancer	0.00165	0.00195	CcSEcCtD
Moclobemide—Confusional state—Docetaxel—ovarian cancer	0.00165	0.00195	CcSEcCtD
Moclobemide—Shock—Docetaxel—ovarian cancer	0.00161	0.0019	CcSEcCtD
Moclobemide—Drowsiness—Doxorubicin—ovarian cancer	0.0016	0.00189	CcSEcCtD
Moclobemide—Tachycardia—Docetaxel—ovarian cancer	0.00159	0.00189	CcSEcCtD
Moclobemide—MAOB—Tryptophan metabolism—CYP1B1—ovarian cancer	0.00159	0.0228	CbGpPWpGaD
Moclobemide—Feeling abnormal—Paclitaxel—ovarian cancer	0.00159	0.00188	CcSEcCtD
Moclobemide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.00159	0.0227	CbGpPWpGaD
Moclobemide—Bradycardia—Epirubicin—ovarian cancer	0.00158	0.00187	CcSEcCtD
Moclobemide—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00157	0.00187	CcSEcCtD
Moclobemide—Stomatitis—Doxorubicin—ovarian cancer	0.00156	0.00185	CcSEcCtD
Moclobemide—Conjunctivitis—Doxorubicin—ovarian cancer	0.00155	0.00184	CcSEcCtD
Moclobemide—CYP2D6—female gonad—ovarian cancer	0.00155	0.0177	CbGeAlD
Moclobemide—Sweating—Doxorubicin—ovarian cancer	0.00153	0.00182	CcSEcCtD
Moclobemide—Urticaria—Paclitaxel—ovarian cancer	0.00153	0.00181	CcSEcCtD
Moclobemide—Hypotension—Docetaxel—ovarian cancer	0.00152	0.00181	CcSEcCtD
Moclobemide—Abdominal pain—Paclitaxel—ovarian cancer	0.00152	0.00181	CcSEcCtD
Moclobemide—Visual impairment—Epirubicin—ovarian cancer	0.00149	0.00177	CcSEcCtD
Moclobemide—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00149	0.0213	CbGpPWpGaD
Moclobemide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00149	0.00176	CcSEcCtD
Moclobemide—Insomnia—Docetaxel—ovarian cancer	0.00148	0.00175	CcSEcCtD
Moclobemide—Paraesthesia—Docetaxel—ovarian cancer	0.00147	0.00174	CcSEcCtD
Moclobemide—Bradycardia—Doxorubicin—ovarian cancer	0.00146	0.00173	CcSEcCtD
Moclobemide—Dyspnoea—Docetaxel—ovarian cancer	0.00145	0.00173	CcSEcCtD
Moclobemide—Somnolence—Docetaxel—ovarian cancer	0.00145	0.00172	CcSEcCtD
Moclobemide—CYP2D6—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.00145	0.0207	CbGpPWpGaD
Moclobemide—Tinnitus—Epirubicin—ovarian cancer	0.00144	0.00171	CcSEcCtD
Moclobemide—MAOA—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.00144	0.0207	CbGpPWpGaD
Moclobemide—Flushing—Epirubicin—ovarian cancer	0.00144	0.00171	CcSEcCtD
Moclobemide—Dyspepsia—Docetaxel—ovarian cancer	0.00144	0.0017	CcSEcCtD
Moclobemide—Decreased appetite—Docetaxel—ovarian cancer	0.00142	0.00168	CcSEcCtD
Moclobemide—Fatigue—Docetaxel—ovarian cancer	0.00141	0.00167	CcSEcCtD
Moclobemide—Constipation—Docetaxel—ovarian cancer	0.0014	0.00166	CcSEcCtD
Moclobemide—Visual impairment—Doxorubicin—ovarian cancer	0.00138	0.00164	CcSEcCtD
Moclobemide—Asthenia—Paclitaxel—ovarian cancer	0.00138	0.00164	CcSEcCtD
Moclobemide—CYP2D6—testis—ovarian cancer	0.00137	0.0157	CbGeAlD
Moclobemide—Pruritus—Paclitaxel—ovarian cancer	0.00136	0.00162	CcSEcCtD
Moclobemide—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.00135	0.0194	CbGpPWpGaD
Moclobemide—Feeling abnormal—Docetaxel—ovarian cancer	0.00134	0.00159	CcSEcCtD
Moclobemide—Tinnitus—Doxorubicin—ovarian cancer	0.00134	0.00159	CcSEcCtD
Moclobemide—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00133	0.00158	CcSEcCtD
Moclobemide—Flushing—Doxorubicin—ovarian cancer	0.00133	0.00158	CcSEcCtD
Moclobemide—Flatulence—Epirubicin—ovarian cancer	0.00133	0.00158	CcSEcCtD
Moclobemide—Tension—Epirubicin—ovarian cancer	0.00132	0.00157	CcSEcCtD
Moclobemide—Dysgeusia—Epirubicin—ovarian cancer	0.00132	0.00157	CcSEcCtD
Moclobemide—Diarrhoea—Paclitaxel—ovarian cancer	0.00132	0.00156	CcSEcCtD
Moclobemide—Nervousness—Epirubicin—ovarian cancer	0.00131	0.00155	CcSEcCtD
Moclobemide—Abdominal pain—Docetaxel—ovarian cancer	0.00129	0.00153	CcSEcCtD
Moclobemide—Dizziness—Paclitaxel—ovarian cancer	0.00127	0.00151	CcSEcCtD
Moclobemide—Vision blurred—Epirubicin—ovarian cancer	0.00127	0.00151	CcSEcCtD
Moclobemide—Ill-defined disorder—Epirubicin—ovarian cancer	0.00125	0.00148	CcSEcCtD
Moclobemide—MAOA—Oxidative Stress—SOD1—ovarian cancer	0.00125	0.0179	CbGpPWpGaD
Moclobemide—Agitation—Epirubicin—ovarian cancer	0.00124	0.00147	CcSEcCtD
Moclobemide—Flatulence—Doxorubicin—ovarian cancer	0.00123	0.00146	CcSEcCtD
Moclobemide—Tension—Doxorubicin—ovarian cancer	0.00122	0.00145	CcSEcCtD
Moclobemide—Vomiting—Paclitaxel—ovarian cancer	0.00122	0.00145	CcSEcCtD
Moclobemide—Dysgeusia—Doxorubicin—ovarian cancer	0.00122	0.00145	CcSEcCtD
Moclobemide—Malaise—Epirubicin—ovarian cancer	0.00122	0.00144	CcSEcCtD
Moclobemide—Rash—Paclitaxel—ovarian cancer	0.00121	0.00144	CcSEcCtD
Moclobemide—Dermatitis—Paclitaxel—ovarian cancer	0.00121	0.00144	CcSEcCtD
Moclobemide—Nervousness—Doxorubicin—ovarian cancer	0.00121	0.00144	CcSEcCtD
Moclobemide—Syncope—Epirubicin—ovarian cancer	0.00121	0.00143	CcSEcCtD
Moclobemide—Headache—Paclitaxel—ovarian cancer	0.00121	0.00143	CcSEcCtD
Moclobemide—Palpitations—Epirubicin—ovarian cancer	0.00119	0.00141	CcSEcCtD
Moclobemide—Loss of consciousness—Epirubicin—ovarian cancer	0.00119	0.00141	CcSEcCtD
Moclobemide—Vision blurred—Doxorubicin—ovarian cancer	0.00118	0.00139	CcSEcCtD
Moclobemide—Asthenia—Docetaxel—ovarian cancer	0.00117	0.00139	CcSEcCtD
Moclobemide—Hypertension—Epirubicin—ovarian cancer	0.00116	0.00138	CcSEcCtD
Moclobemide—Ill-defined disorder—Doxorubicin—ovarian cancer	0.00116	0.00137	CcSEcCtD
Moclobemide—Pruritus—Docetaxel—ovarian cancer	0.00115	0.00137	CcSEcCtD
Moclobemide—Chest pain—Epirubicin—ovarian cancer	0.00115	0.00136	CcSEcCtD
Moclobemide—Myalgia—Epirubicin—ovarian cancer	0.00115	0.00136	CcSEcCtD
Moclobemide—Agitation—Doxorubicin—ovarian cancer	0.00115	0.00136	CcSEcCtD
Moclobemide—Anxiety—Epirubicin—ovarian cancer	0.00114	0.00136	CcSEcCtD
Moclobemide—Nausea—Paclitaxel—ovarian cancer	0.00114	0.00136	CcSEcCtD
Moclobemide—Discomfort—Epirubicin—ovarian cancer	0.00113	0.00135	CcSEcCtD
Moclobemide—Malaise—Doxorubicin—ovarian cancer	0.00113	0.00133	CcSEcCtD
Moclobemide—MAOA—Oxidative Stress—SOD2—ovarian cancer	0.00113	0.0161	CbGpPWpGaD
Moclobemide—Dry mouth—Epirubicin—ovarian cancer	0.00112	0.00133	CcSEcCtD
Moclobemide—Syncope—Doxorubicin—ovarian cancer	0.00112	0.00133	CcSEcCtD
Moclobemide—Diarrhoea—Docetaxel—ovarian cancer	0.00112	0.00132	CcSEcCtD
Moclobemide—Confusional state—Epirubicin—ovarian cancer	0.00111	0.00132	CcSEcCtD
Moclobemide—Palpitations—Doxorubicin—ovarian cancer	0.0011	0.00131	CcSEcCtD
Moclobemide—Loss of consciousness—Doxorubicin—ovarian cancer	0.0011	0.0013	CcSEcCtD
Moclobemide—Shock—Epirubicin—ovarian cancer	0.00108	0.00128	CcSEcCtD
Moclobemide—Dizziness—Docetaxel—ovarian cancer	0.00108	0.00128	CcSEcCtD
Moclobemide—Hypertension—Doxorubicin—ovarian cancer	0.00108	0.00128	CcSEcCtD
Moclobemide—Tachycardia—Epirubicin—ovarian cancer	0.00107	0.00127	CcSEcCtD
Moclobemide—Hyperhidrosis—Epirubicin—ovarian cancer	0.00106	0.00126	CcSEcCtD
Moclobemide—Chest pain—Doxorubicin—ovarian cancer	0.00106	0.00126	CcSEcCtD
Moclobemide—Myalgia—Doxorubicin—ovarian cancer	0.00106	0.00126	CcSEcCtD
Moclobemide—Anxiety—Doxorubicin—ovarian cancer	0.00106	0.00126	CcSEcCtD
Moclobemide—Discomfort—Doxorubicin—ovarian cancer	0.00105	0.00124	CcSEcCtD
Moclobemide—MAOB—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.00104	0.0149	CbGpPWpGaD
Moclobemide—Dry mouth—Doxorubicin—ovarian cancer	0.00104	0.00123	CcSEcCtD
Moclobemide—Vomiting—Docetaxel—ovarian cancer	0.00104	0.00123	CcSEcCtD
Moclobemide—Rash—Docetaxel—ovarian cancer	0.00103	0.00122	CcSEcCtD
Moclobemide—Hypotension—Epirubicin—ovarian cancer	0.00103	0.00122	CcSEcCtD
Moclobemide—Dermatitis—Docetaxel—ovarian cancer	0.00103	0.00122	CcSEcCtD
Moclobemide—Confusional state—Doxorubicin—ovarian cancer	0.00103	0.00122	CcSEcCtD
Moclobemide—Headache—Docetaxel—ovarian cancer	0.00102	0.00121	CcSEcCtD
Moclobemide—CYP1A2—Estrogen Receptor Pathway—CYP1B1—ovarian cancer	0.00101	0.0145	CbGpPWpGaD
Moclobemide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.001	0.00119	CcSEcCtD
Moclobemide—Shock—Doxorubicin—ovarian cancer	0.001	0.00119	CcSEcCtD
Moclobemide—Insomnia—Epirubicin—ovarian cancer	0.000996	0.00118	CcSEcCtD
Moclobemide—Tachycardia—Doxorubicin—ovarian cancer	0.000994	0.00118	CcSEcCtD
Moclobemide—Paraesthesia—Epirubicin—ovarian cancer	0.000988	0.00117	CcSEcCtD
Moclobemide—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000985	0.00117	CcSEcCtD
Moclobemide—Dyspnoea—Epirubicin—ovarian cancer	0.000981	0.00116	CcSEcCtD
Moclobemide—Somnolence—Epirubicin—ovarian cancer	0.000979	0.00116	CcSEcCtD
Moclobemide—Nausea—Docetaxel—ovarian cancer	0.000969	0.00115	CcSEcCtD
Moclobemide—Dyspepsia—Epirubicin—ovarian cancer	0.000969	0.00115	CcSEcCtD
Moclobemide—Decreased appetite—Epirubicin—ovarian cancer	0.000957	0.00113	CcSEcCtD
Moclobemide—Hypotension—Doxorubicin—ovarian cancer	0.000952	0.00113	CcSEcCtD
Moclobemide—Fatigue—Epirubicin—ovarian cancer	0.000949	0.00113	CcSEcCtD
Moclobemide—Constipation—Epirubicin—ovarian cancer	0.000941	0.00112	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000928	0.0011	CcSEcCtD
Moclobemide—Insomnia—Doxorubicin—ovarian cancer	0.000921	0.00109	CcSEcCtD
Moclobemide—Paraesthesia—Doxorubicin—ovarian cancer	0.000915	0.00108	CcSEcCtD
Moclobemide—Dyspnoea—Doxorubicin—ovarian cancer	0.000908	0.00108	CcSEcCtD
Moclobemide—Feeling abnormal—Epirubicin—ovarian cancer	0.000907	0.00108	CcSEcCtD
Moclobemide—Somnolence—Doxorubicin—ovarian cancer	0.000905	0.00107	CcSEcCtD
Moclobemide—Gastrointestinal pain—Epirubicin—ovarian cancer	0.0009	0.00107	CcSEcCtD
Moclobemide—Dyspepsia—Doxorubicin—ovarian cancer	0.000897	0.00106	CcSEcCtD
Moclobemide—Decreased appetite—Doxorubicin—ovarian cancer	0.000885	0.00105	CcSEcCtD
Moclobemide—CYP2C19—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000883	0.0127	CbGpPWpGaD
Moclobemide—Fatigue—Doxorubicin—ovarian cancer	0.000878	0.00104	CcSEcCtD
Moclobemide—Urticaria—Epirubicin—ovarian cancer	0.000874	0.00104	CcSEcCtD
Moclobemide—Constipation—Doxorubicin—ovarian cancer	0.000871	0.00103	CcSEcCtD
Moclobemide—Abdominal pain—Epirubicin—ovarian cancer	0.00087	0.00103	CcSEcCtD
Moclobemide—Feeling abnormal—Doxorubicin—ovarian cancer	0.000839	0.000995	CcSEcCtD
Moclobemide—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000833	0.000988	CcSEcCtD
Moclobemide—CYP2D6—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000812	0.0116	CbGpPWpGaD
Moclobemide—Urticaria—Doxorubicin—ovarian cancer	0.000809	0.00096	CcSEcCtD
Moclobemide—Abdominal pain—Doxorubicin—ovarian cancer	0.000805	0.000955	CcSEcCtD
Moclobemide—CYP2C9—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000805	0.0115	CbGpPWpGaD
Moclobemide—Asthenia—Epirubicin—ovarian cancer	0.00079	0.000937	CcSEcCtD
Moclobemide—Pruritus—Epirubicin—ovarian cancer	0.000779	0.000924	CcSEcCtD
Moclobemide—CYP1A2—Estrogen metabolism—CYP1B1—ovarian cancer	0.000778	0.0112	CbGpPWpGaD
Moclobemide—Diarrhoea—Epirubicin—ovarian cancer	0.000753	0.000893	CcSEcCtD
Moclobemide—Asthenia—Doxorubicin—ovarian cancer	0.000731	0.000867	CcSEcCtD
Moclobemide—Dizziness—Epirubicin—ovarian cancer	0.000728	0.000863	CcSEcCtD
Moclobemide—MAOA—Transmission across Chemical Synapses—NSF—ovarian cancer	0.000726	0.0104	CbGpPWpGaD
Moclobemide—Pruritus—Doxorubicin—ovarian cancer	0.000721	0.000855	CcSEcCtD
Moclobemide—Vomiting—Epirubicin—ovarian cancer	0.0007	0.00083	CcSEcCtD
Moclobemide—Diarrhoea—Doxorubicin—ovarian cancer	0.000697	0.000826	CcSEcCtD
Moclobemide—Rash—Epirubicin—ovarian cancer	0.000694	0.000823	CcSEcCtD
Moclobemide—Dermatitis—Epirubicin—ovarian cancer	0.000693	0.000822	CcSEcCtD
Moclobemide—Headache—Epirubicin—ovarian cancer	0.00069	0.000818	CcSEcCtD
Moclobemide—CYP1A2—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000688	0.00986	CbGpPWpGaD
Moclobemide—CYP2C19—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000682	0.00978	CbGpPWpGaD
Moclobemide—Dizziness—Doxorubicin—ovarian cancer	0.000673	0.000799	CcSEcCtD
Moclobemide—Nausea—Epirubicin—ovarian cancer	0.000654	0.000775	CcSEcCtD
Moclobemide—MAOA—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000653	0.00936	CbGpPWpGaD
Moclobemide—Vomiting—Doxorubicin—ovarian cancer	0.000648	0.000768	CcSEcCtD
Moclobemide—Rash—Doxorubicin—ovarian cancer	0.000642	0.000762	CcSEcCtD
Moclobemide—Dermatitis—Doxorubicin—ovarian cancer	0.000642	0.000761	CcSEcCtD
Moclobemide—Headache—Doxorubicin—ovarian cancer	0.000638	0.000757	CcSEcCtD
Moclobemide—CYP1A2—Estrogen Receptor Pathway—ESR1—ovarian cancer	0.000634	0.00909	CbGpPWpGaD
Moclobemide—CYP2D6—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000627	0.00899	CbGpPWpGaD
Moclobemide—Nausea—Doxorubicin—ovarian cancer	0.000605	0.000718	CcSEcCtD
Moclobemide—MAOA—Neuronal System—NSF—ovarian cancer	0.000556	0.00797	CbGpPWpGaD
Moclobemide—MAOB—Biological oxidations—CYP1B1—ovarian cancer	0.000553	0.00792	CbGpPWpGaD
Moclobemide—CYP1A2—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000531	0.00762	CbGpPWpGaD
Moclobemide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000519	0.00744	CbGpPWpGaD
Moclobemide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000473	0.00679	CbGpPWpGaD
Moclobemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000451	0.00646	CbGpPWpGaD
Moclobemide—CYP2C19—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000441	0.00632	CbGpPWpGaD
Moclobemide—CYP2C9—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000402	0.00577	CbGpPWpGaD
Moclobemide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000385	0.00552	CbGpPWpGaD
Moclobemide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000381	0.00547	CbGpPWpGaD
Moclobemide—CYP2C19—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000376	0.00539	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	0.000367	0.00527	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	0.000367	0.00527	CbGpPWpGaD
Moclobemide—CYP1A2—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000367	0.00527	CbGpPWpGaD
Moclobemide—CYP1A2—Estrogen Receptor Pathway—STAT3—ovarian cancer	0.000355	0.00509	CbGpPWpGaD
Moclobemide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000351	0.00503	CbGpPWpGaD
Moclobemide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000348	0.00498	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—CYP1B1—ovarian cancer	0.000347	0.00497	CbGpPWpGaD
Moclobemide—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000346	0.00496	CbGpPWpGaD
Moclobemide—CYP1A2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000344	0.00493	CbGpPWpGaD
Moclobemide—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000343	0.00492	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—NME2—ovarian cancer	0.000337	0.00483	CbGpPWpGaD
Moclobemide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000309	0.00443	CbGpPWpGaD
Moclobemide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000297	0.00426	CbGpPWpGaD
Moclobemide—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000293	0.0042	CbGpPWpGaD
Moclobemide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000284	0.00407	CbGpPWpGaD
Moclobemide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000282	0.00404	CbGpPWpGaD
Moclobemide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000241	0.00345	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000231	0.00331	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CYTB—ovarian cancer	0.000217	0.00311	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—NME2—ovarian cancer	0.000211	0.00303	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PPP1CC—ovarian cancer	0.00019	0.00272	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—BRIP1—ovarian cancer	0.00019	0.00272	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—CYP1B1—ovarian cancer	0.000164	0.00235	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.000164	0.00235	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000162	0.00232	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.000157	0.00225	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	0.000157	0.00225	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	0.000157	0.00225	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	0.000153	0.0022	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	0.000151	0.00217	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	0.000151	0.00216	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	0.00015	0.00215	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000149	0.00213	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000148	0.00212	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CYTB—ovarian cancer	0.000136	0.00195	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	0.000133	0.00191	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	0.00013	0.00187	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	0.000129	0.00185	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	0.000128	0.00183	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—YAP1—ovarian cancer	0.000127	0.00183	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000127	0.00181	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000126	0.00181	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	0.00012	0.00172	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PPP1CC—ovarian cancer	0.000119	0.00171	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—BRIP1—ovarian cancer	0.000119	0.00171	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	0.000117	0.00168	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	0.000117	0.00168	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	0.000117	0.00168	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000115	0.00165	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	0.000111	0.00159	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—FASN—ovarian cancer	0.000104	0.00149	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—SLC5A5—ovarian cancer	0.000102	0.00146	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—NME2—ovarian cancer	0.0001	0.00143	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	9.86e-05	0.00141	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—SLC2A1—ovarian cancer	9.86e-05	0.00141	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—MAPK1—ovarian cancer	9.82e-05	0.00141	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CYP1B1—ovarian cancer	9.45e-05	0.00136	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	9.42e-05	0.00135	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL6—ovarian cancer	9.21e-05	0.00132	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—NME2—ovarian cancer	9.2e-05	0.00132	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—NME2—ovarian cancer	9.12e-05	0.00131	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	8.49e-05	0.00122	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PPP2R1A—ovarian cancer	8.38e-05	0.0012	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—YAP1—ovarian cancer	7.99e-05	0.00115	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—HRAS—ovarian cancer	7.88e-05	0.00113	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—NME2—ovarian cancer	7.8e-05	0.00112	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—ABCB1—ovarian cancer	7.78e-05	0.00112	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	7.74e-05	0.00111	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—TYMS—ovarian cancer	7.64e-05	0.0011	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—MAPK1—ovarian cancer	7.52e-05	0.00108	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	6.92e-05	0.000992	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	6.61e-05	0.000948	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—FASN—ovarian cancer	6.51e-05	0.000934	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CYTB—ovarian cancer	6.45e-05	0.000925	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—SLC5A5—ovarian cancer	6.4e-05	0.000918	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	6.31e-05	0.000905	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	6.3e-05	0.000904	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—SLC2A1—ovarian cancer	6.19e-05	0.000887	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CAV1—ovarian cancer	6.16e-05	0.000883	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—HRAS—ovarian cancer	6.04e-05	0.000866	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CYTB—ovarian cancer	5.93e-05	0.00085	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CYP1B1—ovarian cancer	5.93e-05	0.00085	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CYTB—ovarian cancer	5.88e-05	0.000843	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	5.75e-05	0.000824	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PPP1CC—ovarian cancer	5.64e-05	0.000808	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—BRIP1—ovarian cancer	5.64e-05	0.000808	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PIK3CG—ovarian cancer	5.61e-05	0.000804	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.39e-05	0.000773	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PPP2R1A—ovarian cancer	5.26e-05	0.000754	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—BRIP1—ovarian cancer	5.18e-05	0.000743	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PPP1CC—ovarian cancer	5.18e-05	0.000743	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PPP1CC—ovarian cancer	5.14e-05	0.000737	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—BRIP1—ovarian cancer	5.14e-05	0.000737	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CYTB—ovarian cancer	5.02e-05	0.00072	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PIK3CD—ovarian cancer	4.93e-05	0.000707	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.91e-05	0.000704	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—ABCB1—ovarian cancer	4.88e-05	0.0007	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—TYMS—ovarian cancer	4.8e-05	0.000688	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—BRIP1—ovarian cancer	4.39e-05	0.00063	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PPP1CC—ovarian cancer	4.39e-05	0.00063	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PIK3CB—ovarian cancer	4.3e-05	0.000616	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.11e-05	0.000589	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CAV1—ovarian cancer	3.86e-05	0.000554	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—YAP1—ovarian cancer	3.78e-05	0.000542	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.75e-05	0.000537	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.74e-05	0.000536	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PTEN—ovarian cancer	3.71e-05	0.000533	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PIK3CG—ovarian cancer	3.52e-05	0.000505	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—YAP1—ovarian cancer	3.48e-05	0.000499	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—YAP1—ovarian cancer	3.45e-05	0.000494	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.41e-05	0.000489	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.29e-05	0.000472	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.2e-05	0.000459	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PIK3CD—ovarian cancer	3.09e-05	0.000444	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—FASN—ovarian cancer	3.08e-05	0.000442	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—SLC5A5—ovarian cancer	3.03e-05	0.000435	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3e-05	0.00043	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—YAP1—ovarian cancer	2.95e-05	0.000422	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—SLC2A1—ovarian cancer	2.93e-05	0.00042	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.92e-05	0.000418	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.87e-05	0.000411	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—FASN—ovarian cancer	2.83e-05	0.000406	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—FASN—ovarian cancer	2.81e-05	0.000403	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CYP1B1—ovarian cancer	2.81e-05	0.000402	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.79e-05	0.0004	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—SLC5A5—ovarian cancer	2.76e-05	0.000396	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PIK3CB—ovarian cancer	2.7e-05	0.000387	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2.69e-05	0.000386	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—SLC2A1—ovarian cancer	2.67e-05	0.000383	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PIK3CA—ovarian cancer	2.62e-05	0.000376	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.61e-05	0.000375	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CYP1B1—ovarian cancer	2.58e-05	0.00037	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.56e-05	0.000367	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CYP1B1—ovarian cancer	2.56e-05	0.000367	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	2.49e-05	0.000357	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.48e-05	0.000355	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—FASN—ovarian cancer	2.4e-05	0.000344	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—SLC5A5—ovarian cancer	2.36e-05	0.000339	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PTEN—ovarian cancer	2.33e-05	0.000334	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—ABCB1—ovarian cancer	2.31e-05	0.000331	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	2.29e-05	0.000328	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—SLC2A1—ovarian cancer	2.28e-05	0.000327	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—TYMS—ovarian cancer	2.27e-05	0.000326	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.27e-05	0.000325	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.26e-05	0.000324	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.23e-05	0.00032	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CYP1B1—ovarian cancer	2.19e-05	0.000314	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—AKT1—ovarian cancer	2.14e-05	0.000307	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—ABCB1—ovarian cancer	2.13e-05	0.000305	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—ABCB1—ovarian cancer	2.11e-05	0.000302	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—TYMS—ovarian cancer	2.09e-05	0.000299	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—TYMS—ovarian cancer	2.07e-05	0.000297	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.94e-05	0.000278	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.93e-05	0.000277	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CAV1—ovarian cancer	1.83e-05	0.000262	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.8e-05	0.000258	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—TYMS—ovarian cancer	1.77e-05	0.000254	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.75e-05	0.000251	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CAV1—ovarian cancer	1.68e-05	0.000241	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CAV1—ovarian cancer	1.67e-05	0.000239	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.67e-05	0.000239	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PIK3CA—ovarian cancer	1.64e-05	0.000236	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.59e-05	0.000228	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.53e-05	0.00022	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.52e-05	0.000218	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.46e-05	0.00021	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CAV1—ovarian cancer	1.43e-05	0.000204	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.36e-05	0.000195	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.35e-05	0.000193	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—AKT1—ovarian cancer	1.34e-05	0.000193	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.34e-05	0.000192	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.3e-05	0.000186	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.28e-05	0.000183	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.17e-05	0.000168	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.16e-05	0.000167	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.14e-05	0.000164	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PTEN—ovarian cancer	1.1e-05	0.000158	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PTEN—ovarian cancer	1.01e-05	0.000145	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PTEN—ovarian cancer	1.01e-05	0.000144	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PIK3CB—ovarian cancer	9.95e-06	0.000143	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PTEN—ovarian cancer	8.6e-06	0.000123	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PIK3CA—ovarian cancer	7.78e-06	0.000112	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PIK3CA—ovarian cancer	7.16e-06	0.000103	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PIK3CA—ovarian cancer	7.1e-06	0.000102	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—AKT1—ovarian cancer	6.36e-06	9.12e-05	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PIK3CA—ovarian cancer	6.06e-06	8.7e-05	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—AKT1—ovarian cancer	5.85e-06	8.39e-05	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—AKT1—ovarian cancer	5.8e-06	8.31e-05	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—AKT1—ovarian cancer	4.95e-06	7.1e-05	CbGpPWpGaD
